STORM THERAPEUTICS
Targeting pathways that modify RNA to deliver novel cancer therapeutics.
STORM THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.stormtherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1223 804174
Total Funding:
69.58 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Tag Manager Google Analytics SSL By Default Global Site Tag ReCAPTCHA Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Board_member
Board_member
2015-09-01
Board_member
2015-09-01
Board_member
2019-07-01
Board_member
2022-09-01
Current Employees Featured
Tony Kouzarides Co-Founder @ Storm Therapeutics
Co-Founder
Gerald McMahon CEO and President @ Storm Therapeutics
CEO and President
2022-09-01
Marguerite Hutchinson Chief Business Officer @ Storm Therapeutics
Chief Business Officer
2023-11-01
Eric Miska Co-Founder @ Storm Therapeutics
Co-Founder
Founder
Investors List
M Ventures
M Ventures investment in Series B - Storm Therapeutics
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Series B - Storm Therapeutics
Seroba Life Sciences
Seroba Life Sciences investment in Series B - Storm Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Storm Therapeutics
UTokyo Innovation Platform
UTokyo Innovation Platform investment in Series B - Storm Therapeutics
Cambridge Innovation Capital
Cambridge Innovation Capital investment in Series B - Storm Therapeutics
Taiho Ventures
Taiho Ventures investment in Series B - Storm Therapeutics
IP Group
IP Group investment in Series B - Storm Therapeutics
Innovate UK
Innovate UK investment in Grant - Storm Therapeutics
M Ventures
M Ventures investment in Series A - Storm Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-11-01 | STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer |
| 2022-09-07 | STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer |
Official Site Inspections
http://www.stormtherapeutics.com Semrush global rank: 10.97 M Semrush visits lastest month: 175
- Host name: web35.extendcp.co.uk
- IP address: 79.170.40.35
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Storm Therapeutics"
STORM Therapeutics - Harnessing the power of RNA …
News. 11th November 2024 STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024. Read more. 9th October 2024See details»
Harnessing the power of RNA epigenetics - STORM Therapeutics
Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience. With broad disease-area expertise and a specialty in oncology …See details»
STORM Therapeutics Limited - LinkedIn
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.See details»
Storm Therapeutics - Craft
Storm Therapeutics has 5 employees across 2 locations and $21.37 m in total funding,. See insights on Storm Therapeutics including office locations, competitors, revenue, financials, …See details»
STORM Therapeutics - Overview, News & Similar companies
Feb 22, 2024 STORM Therapeutics contact info: Phone number: +44 2039509144 Website: www.stormtherapeutics.com What does STORM Therapeutics do? STORM Therapeutics, …See details»
STORM Therapeutics - PitchBook
STORM Therapeutics General Information Description. Operator of a biotechnology and drug discovery company intended to develop small molecule therapies for RNA modification enzymes for use in the treatment of cancer …See details»
Storm Therapeutics - Crunchbase Company Profile
STC-15: An oral small molecule inhibitor of the RNA methyltransferase METTL3, used in oncology to inhibit tumor growth and activate anti-cancer immune responses.See details»
Press releases - STORM Therapeutics
May 24, 2024 For more information, please visit www.stormtherapeutics.com. ... Founded in 1964, the American Society of Clinical Oncology is the world's leading professional …See details»
STORM Therapeutics Ltd. (STORM Therapeutics Ltd.) - 药物管线_ …
For more information, please visit www.stormtherapeutics.com About STC-15 STORM’s lead product, STC-15, is the first RME inhibitor to enter human clinical evaluation. This agent is an …See details»
STORM Therapeutics Presents New Clinical Data on its First-in …
Nov 11, 2024 For more information, please visit www.stormtherapeutics.com. About STC-15 ... hosted by the leading member-driven organization focused on cancer immunotherapy, SITC. …See details»
STORM Therapeutics Presented Interim Phase 1 Clinical Data on its ...
Jun 3, 2024 For more information, please visit www.stormtherapeutics.com . ... Founded in 1964, the American Society of Clinical Oncology is the world's leading professional …See details»
Oliver Rausch - phone & email - Storm Therapeutics Limited
Oliver Rausch is the Chief Scientific Officer of Storm Therapeutics Limited. Storm Therapeutics Limited is a Biotechnology company and has headquarters in Cambridge,. Storm Therapeutics …See details»
STORM Therapeutics announces closing of USD $30M Series B …
Dec 14, 2022 Proceeds will advance STORM's potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias; Financing will further expand STORM's …See details»
Press releases - STORM Therapeutics
Jun 17, 2024 info@stormtherapeutics.com. Optimum Strategic Communications Hana Malik, Zoe Bolt, Elena Bates Tel: +44 (0)203 882 9621 storm@optimumcomms.com NOTES TO …See details»
STORM Therapeutics doses first patient with oral METTL3 …
Nov 23, 2022 For more information, please visit www.stormtherapeutics.com About STC-15 STORM's lead program STC-15 is a first-in-class clinical candidate and is the first inhibitor of …See details»
STORM Therapeutics to Present Data on its First-in-Class METTL1 …
Mar 26, 2024 Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and …See details»
Harnessing the power of RNA epigenetics - STORM Therapeutics
Clinical trials. STORM’s lead clinical program STC-15 is a first-in-class inhibitor of RNA modification and is the first ever RNA methyltransferase inhibitor to enter clinical development.See details»
Press releases - STORM Therapeutics
Jun 3, 2024 For more information, please visit www.stormtherapeutics.com ... Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for …See details»
STORM Therapeutics to Present Findings on its First-in-Class …
Feb 22, 2024 Data demonstrates pharmacological inhibition of METTL1 inhibits tumour growth and reduces tRNA methylation and stability of tRNAs; CAMBRIDGE, England, Feb. 22, 2024 …See details»
Press releases - STORM Therapeutics
Oct 14, 2021 For more information, please visit www.stormtherapeutics.com and engage with us on Twitter @storm_tx or on LinkedIn. STORM Media Contact: Optimum Strategic …See details»